| INTRODUCTION
Patients chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) are at high risk of developing chronic liver disease, cirrhosis and hepatocellular carcinoma. [1] [2] [3] HBV and HCV co-infection further increases liver disease progression and its associated complications. [4] [5] [6] Due to shared routes of transmission, HBV/HCV co-infection is especially common in HBV endemic areas, where HCV infection may be found in up to 10% of HBV-infected individuals. 7 In countries with low HBV seroprevalence, co-infected individuals are rare. However, the prevalence of patients with resolved HBV infection (HBsAg-negative/HBcAb-positive) is reported to be up to 35% in the HCV-infected population. [8] [9] [10] With the introduction of interferon-free, direct-acting antivirals (DAAs), treatment of HCV-infected patients has been revolutionised, with significantly increased sustained virologic response (SVR) rates and overall good tolerability. 11, 12 Yet, concerns have been raised treating HCV patients with previously inactive or even resolved HBV co-infection as to possible HBV reactivation. HBV reactivation, defined as the sudden increase or reappearance of HBV DNA has been well characterised in patients undergoing immunosuppressive or cancer therapy. [13] [14] [15] A recent search of the U.S. Food & Drug Administration (FDA)
Adverse Event Reporting System database identified 29 cases of HBV reactivation with heterogeneous baseline HBV viral parameters, HCV genotypes and DAA regimens. 16 Three of these 29 patients developed liver failure due to HBV reactivation, two of whom died, and one required liver transplantation. This series also included three cases of HBV reactivation in patients with previously resolved HBV infection, who were negative for HBsAg but positive for HBc antibodies. As a consequence, the FDA issued a Boxed Warning concerning the risk of HBV reactivation in patients with current and previous HBV infection who are treated with DAAs for hepatitis C. 17 Therefore, simultaneous HBV treatment has been proposed for inactive HBV carriers and even those with positivity for HBc antibodies only who are treated with DAAs for HCV. 18 In the present study, we retrospectively investigated the incidence of HBV reactivation in a large European single-centre cohort of HCV-infected patients of mixed ethnicities and different HCV genotypes undergoing DAA-based therapies, including regimens with and without pegylated interferon (IFN) alfa.
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according to the manufacturer's instructions, as described previously. 22, 23 The COBAS AmpliPrep/COBAS TaqMan HBV assay has a lower limit of quantification of 20 IU/mL.
HBV DNA was also tested at baseline and repeated time points during and after antiviral therapy in all HBsAg-positive patients at the treating physician's discretion.
| Statistics
All statistical analyses were performed using GraphPad Prism version 5 for Mac (La Jolla, CA, USA). Descriptive statistics are shown as mean AE standard deviation (SD) or median and range. Differences in baseline parameters between HBcAb-positive and HBcAb-negative patients were calculated using the nonparametric Mann-Whitney U test or Fisher's exact test, where appropriate. P<.05 was considered statistically significant.
| Ethics statement
The study was conducted according to the declaration of Helsinki.
The ethics committee of the University Hospital Frankfurt approved the retrospective analysis of anonymous patient data and left over plasma samples.
| RESULTS
A total of 848 patients with chronic HCV infection were treated with different DAA-based regimens in our clinic between January 2014 und July 2016. Twenty-six of these patients (3%) were lost to follow-up and were excluded from all further analyses. Table 2 . HBV DNA was measured at end of treatment in 260 of the 263 patients (99%; serum samples were not available in three patients).
HBV DNA was undetectable in 252/260 patients, whereas in 8/260 patients, HBV DNA was detectable but not quantifiable (<20 IU/mL). Seven of these eight patients had elevated ALT levels at baseline, which declined to normal levels at end of treatment and follow-up (one patient with normal ALT at baseline also showed a decline in ALT levels during treatment and follow-up).
Two of the 263 HBsAg-negative/HBcAb-positive patients were co-infected with HIV, both of whom continuously received tenofovir as part of their antiretroviral regimen. In addition, there were eight post-liver transplant patients who were treated with immunosuppressants (tacrolimus AE mycofenolate mofetil).
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at follow-up, accompanied by elevated ALT levels, was also started on tenofovir 40 weeks after DAA therapy. The clinical courses of all nine HBsAg-positive patients are shown in Table 3 .
| DISCUSSION
Screening for the presence of HBV serologic markers before initiation of HCV therapy is recommended by clinical practice guidelines 19, 24 as HBV reactivation has been observed in up to 31% of patients after successful HCV eradication with interferon-based therapies. [25] [26] [27] Recent reports suggest that this may also be the case in HBV/HCV co-infected patients treated with DAAs, usually within the first weeks of DAA therapy, [27] [28] [29] [30] [31] [32] [33] [34] although the underlying pathophysiology is not yet completely understood. 35 In these reports, More alarmingly, there is potential evidence that HBV reactivation in association with HCV treatment may also occur in patients with resolved HBV infection (HBsAg-negative/HBcAb-positive), a constellation usually associated with strong immunosuppressive therapy. 38 Importantly, the Black Box Warning issued by the FDA explicitly included patients with resolved HBV infection, although only very few case reports have been published so far. [28] [29] [30] 32 This may implicate the use of preemptive nucleos(t)ide therapy in all HBsAgnegative/HBcAb-positive patients undergoing DAA treatment for HCV. This is remarkable against the background of several thousands of HCV patients who participated in DAA phase II and phase III studies and who may have been positive but were never tested for HBc antibodies, whereas HBsAg positivity was always excluded. As expected, the number of co-infected HBsAg-positive patients was low in our study (1%). However, among the patients with positive HBsAg at baseline, 5/9 patients (56%) experienced HBV reactivation during or after DAA-based treatment and this is in line with the findings from other HBsAg-positive cohort studies. 34, 37 In our series, one patient required nucleotide therapy early during DAA therapy and three more patients were started on anti-HBV treatment after DAA treatment completion. Thus, there is little doubt that patients with co-infection who meet the criteria for starting treatment in mono-infected patients (ie, HBV DNA >2000 IU/mL) should also be treated with nucleos(t)ide analogues during DAA therapy, whereas close monitoring of HBV DNA and ALT levels may be sufficient in patients with low-level HBV viremia according to current AASLD/IDSA guidelines. 24 In contrast, the T A B L E 3 Characteristics of HBsAg-positive/HBcAb-positive patients (n=9) with chronic HCV infection treated with direct-acting antivirals (DAAs This patient was also co-infected with HIV and received antiretroviral therapy involving TDF.
